For a long time, as the most prominent subnuclear structure, nucleolus has been recognized as a main site where rRNA processing and ribosomal subunit assemblies take place. It has not been until recently that additional functions of nucleolus have begun to be proposed. In this study, we for the first time demonstrate that SurvivindeltaEx3, a novel functionally splice variant of Survivin localizes in the nucleoli where it degrades rapidly through ubiquitin-proteosome pathway. Several lines of evidences provided in this report support this finding (i) a novel nucleolar localization sequence (NoLS, MQRKPTIRRKNLRLRRK) and a novel degradation signal (aa92-aa137) within Survivin-deltaEx3 were identified (ii) proteasome inhibitors MG132 or ALLN greatly inhibits degradation of Survivin-deltaEx3 and polyubiquitination of Survivin-deltaEx3 was detected (iii) heterologous proteins such as TAT-PTD or p14ARF, when fused to this putative degradation signal, result in a significant degradation within the nucleolus. In addition, the nucleolar localization and degradation of SurvivindeltaEx3 appear to be required for its antiapoptotic function, since neither NoLS-deleted nor degradation signal-deleted Survivin-deltaEx3 retains protective effect against Doxorubicin-induced apoptosis. Thus, our results have provided evidences to suggest that besides cytosol, nucleus, endoplsmic reticulum (ER) or lysosomes, nucleolus may also operate important protein degradation pathway, which has been overlooked previously.
For a long time, as the most prominent subnuclear structure, nucleolus has been recognized as a main site where rRNA processing and ribosomal subunit assemblies take place. It has not been until recently that additional functions of nucleolus have begun to be proposed. In this study, we for the first time demonstrate that SurvivindeltaEx3, a novel functionally splice variant of Survivin localizes in the nucleoli where it degrades rapidly through ubiquitin-proteosome pathway. Several lines of evidences provided in this report support this finding (i) a novel nucleolar localization sequence (NoLS, MQRKPTIRRKNLRLRRK) and a novel degradation signal (aa92-aa137) within Survivin-deltaEx3 were identified (ii) proteasome inhibitors MG132 or ALLN greatly inhibits degradation of Survivin-deltaEx3 and polyubiquitination of Survivin-deltaEx3 was detected (iii) heterologous proteins such as TAT-PTD or p14ARF, when fused to this putative degradation signal, result in a significant degradation within the nucleolus. In addition,
Introduction
Increasing resistance to apoptosis resulted from an imbalance between proapoptotic and antiapoptotic proteins plays a critical role during tumorigenesis and tumor progression, facilitating the accumulation of transforming mutations and promoting escape of tumor cells from immunosurveillance (Rudin and Thompson, 1997) . Survivin (SVV) was identified as a smallest known IAP family protein (16.5 kDa), which contains a single BIR domain and an extended carboxy-terminal coiled-coil structure (Ambrosini et al., 1997; Li et al., 1998a, b) . Its expression is important for cell survival and chemoresistance of certain carcinomas (Ambrosini et al., 1997; Satyamoorthy et al., 2001) . SurvivindeltaEx3 (SVV-deltaEx3), functioning as an antiapoptotic protein, is a naturally occurring splice variant of human Survivin and has been shown to express in both cancer cells and fetal tissues (Mahotka et al., 1999; Krieg et al., 2002; Wang et al., 2002) . SVV-deltaEx3 lacks exon 3 of wild-type SVV, resulting in an interrupted BIR domain and a frame shift, which creates a novel 63-amino-acid-long C-terminus resembling the K7 protein of Kaposi's sarcoma-associated herpesvirus (KSHV) (Mahotka et al., 1999; Wang et al., 2002) . It has been reported that although the expression level of another Survivin splice variant Survivin-2B (a non-antiapoptotic protein) is significantly decreased in advanced stages of gastric cancer, levels of Survivin and SVV-deltaEx3 remain unchanged (Krieg et al., 2002) , suggesting that both SVV and SVV-deltaEx3 might provide a growth advantage for tumors and possibly also contribute to chemoresistance in cancer. These observations suggest that exploring the functions and regulations of Survivin and its splice variants would become an important research topic in this field.
The nucleolus is a specialized site of the nucleus in which transcription and processing of rRNA and ribosome assembly take place (Carmo-Fonseca et al., 2000) . However, more and more nonribosomal proteins including growth factors (Antoine et al., 1997; Galcheva-Gargova et al., 1998; Pederson, 1998a, b) , virus proteins (Stauber and Pavlakis, 1998; Wurm et al., 2001 ) and regulators of apoptosis such as p53, DEDD, MDM2 and p14ARF (Stegh et al., 1998; Zhang and Xiong, 1999; Lohrum et al., 2000) were demonstrated to localize in this sub-nuclear organelle under certain conditions. It has been well documented that a cluster of basic amino acids could lead heterologous proteins into the nucleus/nucleolus (Kaffman and O'Shea, 1999) , however, no consensus motifs have been characterized thus far for nucleolus targeting and the mechanism underlying nucleolar distribution still remains largely obscure.
Rapid turnover of regulatory proteins is an essential step in many central biological processes including signal transduction and cell cycle control. Downregulation of these proteins often occurs by specific proteolysis mediated by the ubiquitin system. The major determinant for protein half-life is the presence of degradation signals including N-degron, the ubiquitin fusion degradation (UFD) signal, the PEST sequence and the destruction box (Varshavsky, 1996; Laney and Hochstrasser, 1999) . Recently, it became evident that the components of the ubiquitin system are not evenly distributed throughout the cell and proteolysis of some specific proteins is restricted to a certain cellular compartment (Lenk and Sommer, 2000) . Although several recent studies indicate that the nuclear structure PODs (PML bodies) may involve the proteasomal degradation of ubiquitinated proteins (Everett et al., 1997) , it has not yet been clear whether nucleolus is associated with proteasomemediated degradation system.
Here, we show that the Survivin splice variant SVVdeltaEx3 is localized in nucleolus upon the treatment of proteasome inhibitors or when it is ectopically expressed in transfected cells. This nucleolus distribution appears to be p53-and cell type-independent. We also identified a novel nucleolar localization signal (NoLS) that is capable of targeting the SVV-deltaEx3 into nucleolus. A deletion version SVV-detaEx3
ÀNoLS lacking NoLS fails to distribute into nucleolus. In addition, we have characterized a novel degradation signal in SVV-deltaEx3, which is responsible for its rapid turnover in the nucleolus via ubiquitin-proteasome pathway. We demonstrated that both NoLS and degradation signal of SVV-deltaEx3 are required for its preserved antiapoptotic function. More importantly, we provided evidences for the first time that the nucleolus could be an active subnuclear organelle, in which proteasome mediated degradation occurs.
Results

SVV-deltaEx3 accumulates in the nucleoli after treatment with proteasome inhibitors
In our previous study, we reported that Survivin localized in cytoplasm in interphase, on chromosome at anaphase and to midbody at telophase (Song et al., 2003 (Song et al., , 2004 . Naturally, we were interested in comparing the cellular distribution of SVV-deltaEX3 with that of SVV. Since no antibodies are currently available to differentiate the subcellular localization of endogenous SVV-deltaEx3 from Survivin, we therefore constructed a series of pEGFP-C1 constructs coding for the GFPtagged different versions of SVV-deltaEx3 to examine their intracellular distributions in living cells ( Figure 1A ). HeLa cells were firstly transfected with various constructs, 24 h later, cells were incubated with DNAstaining dye Hoechst 33342 (2 mg/ml) for 30 min, and were then examined under UV with fluorescence microscope. The GFP system allowed us to follow the intracellular localization of specifically labeled proteins in living cells. As shown in Figure 1B /a, GFP protein displayed an evenly diffused localization throughout the cells and did not show subcellular organelle-specific locations, indicating GFP by itself does not influence the distribution of its fusion partner. GFP/Survivin was expected to be localized in cytoplasm and excluded from the nucleus during interphase ( Figure 1B/a) , however, much to our surprise, GFP/SVV-deltaEx3 exhibited mainly the nuclear distribution ( Figure 1B We next examined the distribution of SVV-deltaEx3 in HeLa cells by treatment of proteasome inhibitors. HeLa cells expressing GFP/SVV-deltaEx3 were cultured in the presence of proteasome inhibitor ALLN (100 mM) or MG132 (10 mM) for 12 h prior to inspection by fluorescence microscope. Without prior notice, predominant amount of SVV-deltaEx3 previously only observed in the nucleoplasm in the absence of inhibitor was emerged in the nucleolus ( Figure 1C/a) . Unlike SVV-deltaEx3, neither GFP nor GFP/Survivin showed nucleolar accumulation after treatment of proteasome inhibitor MG132 ( Figure 1C/b) . In order to further verify the nucleolar localization of SVV-deltaEx3, we compared the localization of SVV-deltaEx3 with that of nucleolin, a major nucleolar protein (Creancier et al., 1993; Schmidt-Zachmann and Nigg, 1993) in HeLa cells coexpressing GFP/SVV-deltaEx3 and DsRed/nucleolin. As shown in Figure 1D , colocalization of SVV-deltaEx3 and nucleolin was observed in the cotransfected cells, since the merged image produces a uniform yellow color (right panel). This result indubitably confirmed our finding that SVV-deltaEx3 exhibit nucleolar accumulation upon proteasome inhibition.
It has been well documented that HeLa cell line is p53-deficient due to the presence of HPV-E6, which degrades endogenous p53. To check whether the intracellular localization of SVV-deltaEx3 is correlated to p53, which is a transcription factor for Survivin, a MCF-7 (p53 þ / þ ) cells were transfected with pEGFP-C1/SVV-deltaEx3. As shown in Figure 1E , SVV-deltaEx3 was shown to localize in nucleus after DMSO treatment (mock control), and became to show nucleolar accumulations in MCF-7 cells after MG132 treatment. These results demonstrated that nucleolus distribution of SVV-deltaEx3 is p53-or cell type-independent.
Identification of a novel nucleolar localization signal (NoLS) in SVV-deltaEx3
Since SVV-deltaEx3 was found to accumulate to nucleoli after treatment with proteasome inhibitors Nucleolar localization and degradation of Survivin-deltaEx3 Z Song and M Wu ( Figure 1C /a), we asked first whether this nucleolus accumulation of SVV-deltaEx3 is due to the transport of SVV-deltaEx3 into nucleolus from nucleoplasm upon the treatment of proteasome inhibitors. Careful inspection of SVV-deltaEx3 distribution in transfected HeLa cells with normal amount of plasmid used for transfection (0.5 mg/24-well plate) revealed that a very small portion of transfected cells (o5%) was shown nucleolar localization of SVV-deltaEx3 in the absence of proteosome inhibitor (Figure 2A /a). To assess whether nucleolar distribution of SVV-deltaEx3 is dependent on its cellular expression level, we progressively increased the amounts of the pEGFP-C1/SVV-deltaEx3 during transfection. As shown in Figure 2A /b, the proportion (numbers of cells with nucleolus distribution/numbers of green fluorescent cells) of cells containing GFP/SVV-deltaEx3 in the nucleoli increased from o5 to o10%, o18, o16 and o17%, when plasmid concentrations were raised from 0.5 to 1, 2, 4 and 8 mg/ well correspondingly. It is clear that 2 mg/well have already reached a plateau, we therefore do not expect the percentage of nucleolar localization will exceed 20% in the absence of MG132. These results demonstrate that nucleolar localization of SVV-deltaEx3 does occur when protein expression level becomes high. Nevertheless, the nucleolus localization resulted from forced expression of SVV-deltaEx3 is not as significant as that from the treatment with proteasome inhibitors (t-test, Po0.05, approximately 18 vs 65%).
The capability of nucleolar lacalization of SVVdeltaEx3 reminds us that SVV-deltaEx3 might contain a nucleolar localization signal (NoLS). To map the NoLS in SVV-deltaEx3, we generated a series of deletion constructs of SVV-deltaEx3 from either the N-terminus or the C-terminus or both in order to determine the minimal region comprising nucleolus targeting signal ( Figure 1A) . The constructs expressing different parts of SVV-deltaEx3 were transfected into HeLa cells and their intracellular distribution were assessed by fluorescence microscope. Since Survivin does not localize in nucleolus, we then assume it does not contain NoLS in its sequence. Realizing that protein fragment ranging from aa1 to aa73 was identical between Survivin and SVV-deltaEx3, it is reasonable to expect that fragment common to both Survivin and SVV-deltaEx3 would have little, if any effects on , which is lacking the fragment (aa1-aa73), and as shown in Figure 2B /a, GFP/SVV-deltaEx3(74-137) exhibited a nucleolus distribution, implying that a potential NoLS may exist within this region (aa74-aa137). When aminoacid sequence of SVV-deltaEx3(74-137) was further compared with some known nucleolus-targeting proteins, we noticed that SVV-deltaEx3(74-137) contains a stretch of basic residues within a shorter region from aa74 to aa91, which was similarly found in other nucleolus-localizing proteins ( Figure 2D ). To further verify whether this short sequence (aa 74-91) truly represents a functional NoLS, we generated three deletion constructs namely SVV-deltaEx3 ( More strikingly, short peptide SVV-deltaEx3(74-91) was able to efficiently lead its fused GFP partner to localize into nucleolus ( Figure 2B /d), suggesting that this putative NoLS 'MQRKPTIRRKNLRKLRRK' (aa74-91) is sufficient to import SVV-deltaEx3 into nucleolus. We further cotransfected plasmids coding for GFP/SVV-deltaEx3(74-91) and DsRed1/nucleolin into HeLa cells, the distributions of expressed proteins were compared. As shown in Figure 2C , GFP/SVV-deltaEx3(74-91) was colocalized with DsRed1/nucleolin and showed perfectly merged yellow spots, and the intranuclear intensity distribution patterns for GFP/ DEx3(74-91) and DsRed/Nucleolin products are pretty much similar (intensity of GFP/DEx3(74-91): intensity of DsRed/Nucleolin is about 11: 10) by quantitative densitometry measurement using Eagle Eye Jr. Still Video System (Stratagene, USA) by an EagleSight software, suggesting that SVV-deltaEx3(74-91) is in fact a novel NoLS. Taken together, our data demonstrate that the sequence 'MQRKPTIRRKNLRKLRRK' in SVV-deltaEx3 represents a novel and functional NoLS.
SVV-deltaEx3 is degraded by the ubiquitin-proteasome pathway
Survivin has been reported to be degraded by the ubiquitin-proteasome pathway through its C-terminus (Zhao et al., 2000) . However, the carboxy-terminus of SVV-deltaEx3 (aa74-137) is completely different from that of Survivin. We inquired whether the unique carboxy-terminus of SVV-deltaEx3 involves in its degradation pathway. Experimental data from our laboratory showed that GFP/SVV-deltaEx3 undergoes more rapid turnover than GFP/Survivin ( Figure 1B/b) , suggesting that the unique C-terminus of SVV-deltaEx3 must have participated in its degradation. To further check whether the degradation of SVV-deltaEx3 is proteasome dependent, HeLa cells were transfected with plasmid expressing GFP/SVV-deltaEx3 in the presence or absence of proteasome inhibitions to examine the protein stability. As shown in Figure 3A /a, levels of GFP/SVV-deltaEx3 were significantly increased in HeLa cells incubated with ALLN (100 mM) or Mg132 (10 mM), compared with that in cells with mock treatment of DMSO, suggesting that GFP/SVV-deltaEx3 is subject to degradation by proteasomes. To further elaborate the GFP/SVV-deltaEx3 degradation pathway, we quantitatively calculated the percentage of the green fluorescent cells to assess the protein stability following transfection with equal amount of plasmids. We found that the percentage of cells expressing GFP did not show any change in the presence or absence of MG132 ( Figure 3A /b), demonstrating that GFP was not subjected to degradation through proteasome pathway, and as a result, any changes in levels of GFP fusion protein by proteasome inhibitor must be due to fusion partner itself. In contrast, the percentage of fluorescent cells expressing GFP/SVV-deltaEx3 increased from >26 to >69% (# of fluorescent cells/# of total cells counted) when MG132 was added ( Figure 3A/b ). These data demonstrate that SVV-deltaEx3 is degraded through proteasome pathway. Since MG132 is a specific inhibitor of ubiquitinproteasome pathway and ubiquitylation has often been linked to degradation through the proteasome, we then asked if SVV-deltaEx3 could be ubiquitylated in living cells. We transfected HeLa cells with construct expressing GFP-tagged SVV-deltaEx3 alone or GFP-tagged SVV-deltaEx3 plus Flag-tagged ubiquitin. At 24 h after transfection, cells were treated with or without MG132 (10 mM) for 12 h and were then lysed for detection of ubiquitylation by Western blot using anti-GFP antibody. As shown in Figure 3B , high-molecular mass products generated from GFP/SVV-deltaEx3 by polyubiquitination were accumulated in Flag/ubiquitin and GFP/SVV-deltaEx3 coexpressed cells treated with MG132, but not seen in cells expressing GFP/SVVdeltaEx3 in the absence of MG132, indicating that SVVdeltaEx3 was truly ubiquitylated in cells. More direct evidences for in vivo ubiquitination of SVV-deltaEx3 came from immunoprecipitation experiment. The same lysate prepared for Western analysis were immunoprecipitated with anti-GFP antibody. In Figure 3C left lane, result of immunoblot revealed a prominent band with expected size corresponding to transfected protein GFP/SVV-deltaEx3. In the right lane, a weak smear or a ladder of high molecular weight of GFP/SVV-deltaEx3 corresponding to ubiquitylated GFP/SVV-deltaEx3 was additionally detected, strongly suggesting that SVVdeltaEx3 is ubiquitinated in vivo.
Identification of a novel degradation signal in SVVdeltaEx3
Degradation of proteins by the ubiquitin system was reported to be mediated by specific degradation signals, which could be motifs or structural features of targeting proteins that are required for rapid proteolysis (Laney and Hochstrasser, 1999). As seen in Figure 1B /b, GFP/ SVV-deltaEx3 degrades more rapidly than GFP/SVV and the steady-state level of GFP/SVV-deltaEx3 was only approximately 1/4 of that of GFP/Survivin, when two cells were transfected with the same amount of plasmid (densitometry data not shown). Since the sequence difference between Survivin and SVV-deltaEx3 resides in their carboxy-terminus (aa 74-137), it is not unreasonable to propose that the carboxy-terminus of SVV-deltaEx3 might be responsible for its quicker turnover. HeLa cells were transfected with vectors expressing GFP/SVV-deltaEx3, GFP/SVV-deltaEx3(74-91), GFP/SVV-deltaEx3(92-137) or GFP separately. After 24 h, cells were treated with or without MG132 (10 mM) for 12 h, and were then examined under fluorescence microscope to evaluate protein stability by counting the percentage of fluorescent cell (see Materials and methods). We found that the percentage of fluorescent cell expressing GFP/SVV-deltaEx3(92-137) (>27%, Figure 4A /a) and GFP/Surv-deltaEx3 (>24%, Figure 4A /a) was significantly lower than that of fluorescent cells expressing GFP (>89%, Figure 3A /b) or GFP/SVV-deltaEx3(74-91) (>71%, Figure 4A /a) in the absence of MG132 (Po0.05, t-test), indicating that SVV-deltaEx3(92-137), similar to SVV-deltaEx3, might be a short-lived protein which is degraded quickly in the nucleolus. However, when cells were treated with MG132, the percentage of fluorescent cells expressing GFP/SVV-deltaEx3(92-137) was increased to the level (>69%, Figure 4A /a) equivalent to GFP/SVV-deltaEx3(74-91) (>73%, Figure 4A /a), suggesting that degradation of GFP/SVV-deltaEx3(92-137) is proteasome dependent. A Western blot analysis was performed to support this conclusion. GFP/SVV-deltaEx3(92-137) expressed HeLa cells were incubated with mock DMSO (in which ALLN and GM132 were dissolved) or proteasome inhibitor ALLN (100 mM) or MG132 (10 mM), as shown in Figure 4A /b, the level of GFP/ SVV-deltaEx3(92-137) was significantly increased in MG132-or ALLN-treated cells compared with that in DMSO-treated cells, indicating that Surv-deltaEx3(92-137) functions as a potential degradation signal. To further strengthen the finding that GFP/SVVdeltaEx3(92-137) is degraded by ubiquitin-proteasome pathway, immunoprecipitation experiments were performed and the immunoprecipitates were detected with anti-GFP antibodies. As shown in Figure 4B , ubiquitinated GFP/SVV-deltaEx3(92-137) were detected only in MG132-treated cells coexpressing both GFP/SVV-deltaEx3(92-137) and Flag-tagged ubiquitin, but not in untreated cells expressing GFP/SVV-deltaEx3(92-137). These results clearly demonstrated that the degradation of GFP/SVV-deltaEx3(92-137) is mediated by ubiquitin-proteasome pathway and confirmed that the SVVdeltaEx3(92-137) is a novel degradation signal sequence.
Both NoLS and degradation signal of SVV-deltaEx3 are essential for its antiapoptotic function
Splice variant SVV-deltaEx3 was reported to have largely preserved its antiapoptotic activity (Mahotka et al., 1999) . To check whether NoLS or degradation signal is essential for this antiapoptotic function, plasmid coding for GFP/SVV-deltaEx3
ÀNoLS (lacking NoLS) or GFP/SVV-deltaEx3(1-91) (a degradation signal deleted form) was transfected into HeLa cells separately, 24 h later, apoptosis inducer doxorubicin (5 mg/ml) was added to culture media for another 24 h incubation. Apoptotic cell percentage was then calculated by counting the fluorescent cells with condensed and/or fragmented nuclei stained by Hochest 33342 (see Materials and methods). As shown in Figure 5A /a, compared with GFP control (>46%), GFP/SVVdeltaEx3 showed a significantly reduced apoptosis (>34%) induced by doxorubicin (Po0.05, t-test), whereas either GFP/SVV-deltaEx3
ÀNoLS or GFP/SVVdeltaEx3(1-91) has lost the antiapoptotic function, demonstrating that both NoLS and degradation signal are necessary for SVV-deltaEx3 to inhibit apoptosis. These results were further confirmed by assessing the activation of caspases by Western blot. As shown in Figure 5A /b, less cleavage of both caspase-9 and -3 were shown in HeLa cells expressing GFP/SVV-deltaEx3 than in cells expressing GFP, GFP/SVV-deltaEx3
ÀNoLS or GFP/SVV-deltaEx3(1-92) upon doxorubicin stimulation (densitometry data not shown). In addition, we have examined the distribution of GFP/SVV-deltaEx3
ÀNoLS , we found that although it preserved its nuclear distribution and displayed a weak cytoplasmic smear, its nucleolar localization capability, however, has been completely vanished ( Figure 5B ). Taken together, we demonstrated that both NoLS and degradation signal are essential for the antiapoptotic function of SVV-deltaEx3.
The nucleolus may be the site for proteasome-mediated protein degradation
From the data presented above, we are much in favor of the hypothesis that that SVV-deltaEx3 exists in nucleolus normally, however, due to its rapid degradation; it is hardly detected in nucleolus without MG132 treatment. To experimentally validate this assumption, we transfected HeLa cells with construct coding for GFP/SVVdeltaEx3, 24 h later, cells were treated with DMSO, MG132 or MG132 plus CHX (cycloheximide, 100 mg/ ml) respectively for another 12 h and the cells were then assessed for their intracellular distributions. As shown in Figure 6A , GFP/SVV-deltaEx3 localized to nucleus and was specifically excluded from the nucleoli when transfected cells were incubated with DMSO alone (approximately 3% of green fluoresced cells with nucleolar localization), and GFP/SVV-deltaEx3 became to be accumulated in nucleoli when cells were treated with MG132 (approximately 82% of green fluoresced cells were found to have nucleolus accumulation of GFP/SVV-deltaEx3). More importantly, within the fluoresced cells cotreated with MG132 and CHX, ÀNoLS or pEGFP-C1/SVV-deltaEx3(92-137) respectively. At 20 h post-transfection, cells were exposed to doxorubicin (5 mg/ml) for 24 h and the percentage of apoptosis of treated cells was then calculated (see Materials and methods). ' þ ' denotes treated with doxorubicin and 'À' untreated. Values are mean7s.d. from three independent experiments. Statistical analysis was used by t-test. *Po0.05. (b) The cell lysates from 'a' were analysed by Western blot using anticaspase 9 and anticaspase 3 antibodies. '1' indicated control (untreat with doxorubicin), '2' denotes GFP, '3' denotes GFP/SVV-deltaEx3, '4' denotes GFP/ SVV-deltaEx3
ÀNoLS and '5' denotes GFP/SVV-deltaEx3(92-137). '2-5' were all treated with doxorubicin. (B) Plasmid pEGFP-C1/ SVV-deltaEx3
ÀNoLS were transfected into HeLa cells and protein GFP/SVV-deltaEx3
ÀNoLS distribution was examined by fluorescence microscope Figure 6 The nucleolus acts as the site for the proteasomemediated protein degradation (A) 20 h after transfection of HeLa cells with pEGFP-C1/SVV-deltaEx3, cells were separately incubated with DMSO, MG132 (10 mM) or MG132 (10 mM) plus CHX (cycloheximide, 100 mg/ml) for another 12 h. The live cells were then examined with fluorescence microscope to check protein distribution. (B) HeLa cells were transfected with pEGFP-C1/SVVdeltaEx3. After 20 h, cells were incubated with ALLN (100 mM) for 12 h, and the live cells were examined by fluorescence microscope for protein localization. Cells were continuously incubated for another 6 h with a new culture media in which ALLN was not added. Protein distribution was by then checked by fluorescence microscope. (C) (a) The protein GFP/TAT-PTD or GFP/TAT-PTD fused with deltaEx3(92-137) at its C-terminal were expressed in HeLa cells, and the live cells were checked with fluorescence microscope. (b) The total cell extracts from (a) were used detection for protein expression levels by Western blot using anti-GFP antibody, and endogenous Tubulin was used as a loading control. (D) (a) Plasmid coding for protein GFP/p14ARF or GFP/p14ARF fused with deltaEx3(92-137) at its C-termianl was transfected into HeLa cells respectively, and the fluoresced cells were compared by fluorescence microscope. (b) Total cell extracts from (a) were used for examining protein expression levels by Western blot using anti-GFP antibodies, and endogenous Tubulin was used as a loading control Nucleolar localization and degradation of Survivin-deltaEx3 Z Song and M Wu majority of GFP/SVV-deltaEx3 failed to accumulate in nucleoli (about 81%). According to our conclusion, the manifestation of nucleolar accumulation of SVV-deltaEx3 resulting from treatment of proteasome inhibitors is due to prevention of degradation of Surv-deltaEx3 in nucleolus. It is naturally expected that nucleolar accumulation of SVV-deltaEx3 would disappear gradually if proteasome inhibitor were taken away from cultured cells. To verify this prediction, we treated GFP/SVV-deltaEx3-transfected HeLa cells with ALLN and changed the cell medium (without adding ALLN) after 12 h. Cells were continued to culture for 6 h before they were examined under microscope. As shown in Figure 6B , GFP/SVV-deltaEx3 was distributed to nucleoli of transfected cells after ALLN treatment (white arrows in the left panel), and as expected, level of nucleolar lacalization of GFP/SVV-deltaEx3 was significantly decreased (white arrows, in the right panel) after 6 h incubation with medium without adding ALLN, demonstrating that proteasome-mediated degradation of GFP/SVV-deltaEx3 did occur in nucleolus.
It is well known that peptide (YGRKKRRQRRR) from HIV-1 encoded trans-activator TAT is a typical NoLS, and the p53-stabilizing protein p14ARF is a bona fide nucleolar protein (Vives et al., 1997; Rizos et al., 2000) . As shown in Figure 6C , fusion protein GFP/ TAT-PTD (protein transduction domain) showed nucleus/nucleolar localization, whereas GFP/p14ARF displayed an even stronger nucleolar distribution. If the conclusion that nucleolus acts as an alternative protein degradation site was true, we would expect that levels of TAT-PTD or p14ARF, when fused with the degradation signal SVV-deltaEx3(92-137), would be significantly reduced within the nucleolus. Protein levels were measured either by counting the numbers of fluorescent cells or by Western blotting using anti-GFP antibody, we concluded that levels of protein GFP/TAT-PTDdeltaEx3(91-137) or GFP/p14ARF-deltaEx3(91-137) was significantly lower than that of GFP/TAT-PTD or GFP/p14ARF ( Figure 6C ), suggesting that the degradation signal SVV-deltaEx3(92-137) was able to accelerate the turnover rate of imported heterologous proteins, such as p14ARF or TAT-PTD. More importantly, results from Figure 6C further strongly imply that SVVdeltaEx3(92-137)-mediated degradation is carried out specifically in nucleolus because remnants of GFP/ p14ARF-deltaEx3(91-137) (not yet degraded proteins) were found to remain only in the nucleolus, but not in any other intracellular organelles ( Figure 6C/b-1) .
Discussion
Survivin is a member of the inhibitor of apoptosis protein (IAP) family that has been implicated in both apoptosis inhibition and cell cycle control (Li et al., 1998a, b; Skoufias et al., 2000; Song et al., 2003 Song et al., , 2004 . While it is undetectable in normal differentiated adult tissues, Survivin is found to express aberrantly in cancer and fetal tissues (Ambrosini et al., 1997; Li, 2003) . It has been reported that both Survivin and its splice variants (SVVdeltaEx3 and SVV-2B) play crucial roles in the preservation of cell viability and maintenance of normal mitotic progression (Altieri, 2003) . In recent years, multiple strategies have been developed for Survivin as a cancer therapeutic target, and growing evidences suggested that quantifying the levels of Survivin and/or its splice variants is useful in the prediction of the biological malignancy of tumors, independent of their pathological aspects (Krieg et al., 2002; Yamada et al., 2003) . SVV-deltaEx3 is a divergent splice variant of Survivin, which lacks the exon 3, resulting in a truncated BIR domain and a unique carboxy terminal sequence unrelated to that of Survivin (Mahotka et al., 1999) .
In this study, we demonstrated for the first time that, unlike Survivin, SVV-deltaEx3 is localized in the nucleoli where it undergoes rapid degradation via ubiquitinproteasome pathway. We identified a novel nocleolar targeting signal (NoLS) and a novel degradation signal in SVV-deltaEx3, which is responsible for the degradation of SVV-deltaEx3 in the nucleolus. In addition, we showed that nucleolar localization of SVV-deltaEx3 and its degradation in this subnuclear organelle are essential for its antiapoptotic function. Structurally speaking, carboxy terminal of SVV-deltaEx3 is completely different from that of Survivin and because of that significant divergence between their C-termini, SVV-deltaEx3 comprises at least three characteristics which are not seen in Survivin: (i) SVV-deltaEx3 contains a novel NoLS, resulting in the nucleolus localization; (ii) SVV-deltaEx3 possesses a novel degradation signal sequence by which it degrades more rapidly than Survivin; and (iii) unlike Survivin, SVV-deltaEx3 does not act as a chromosome passenger protein during the cell cycle (data not shown). Taken together, these new properties of SVV-deltaEx3 will provide more information to improve our understanding of manifold functions of both Survivin and its splice variants. Survivin, as a single gene, is able to express three proteins including Survivin, SVV-deltaEx3 and SVV-2B by alternative splicing. Although each of them has some overlapping functions, yet they all have their own unique roles to play in the process of cell survival, which might be part of the reasons why tumors are usually so resistant to irradiation and chemotherapeutic drugs.
As the most prominent sub-nuclear structure, the nucleolus has a well-established role in ribosomal subunit assembly. However, additional functions of nucleolus, including roles in viral infections, nuclear export, sequestration of regulatory molecules, modification of small RNAs, RNP assembly, regulation of tumor suppressors and control of aging, have been proposed recently (Pederson, 1998a, b; Olson et al., 2000 Olson et al., , 2002 . Ubiquitin-proteasome-mediated protein degradation is an important general mechanism by which cells regulate and/or maintain their protein levels and accordingly their functions at specific times and sites. Recently, it has been demonstrated that the components of the ubiquitin system are not evenly distributed throughout the cell (Lenk and Sommer, 2000) . One example for the compartmentalization of the system is endoplasmic reticulum associated protein degradation (ERAD) (Sommer and Wolf, 1997; Bonifacino and Weissman, 1998) . It has been demonstrated that the nuclear structure PODs (also termed nuclear domain 10/ND10 or PML bodies), were also found to associate with ubiquitinated protein degradation (Everett et al., 1997) . In addition, proteasomes have been reported to localize to nucleolus after treatment of proteasome inhibitors (Everett et al., 1997; Arabi et al., 2003) . However, whether nucleolus is involved in proteasomal degradation has not been systematically reported thus far. In the present study, we have demonstrated that SVV-deltaEx3 was greatly accumulated in the nucleolus upon treatment with proteasome inhibitors ( Figure 1C ). There are two possibilities to explain this phenomenon: one is that SVV-deltaEx3 transported into nucleolus by proteasome inhibitor, and the alternative is SVV-deltaEx3 normally locates within nucleolus, but is hardly be detected due to it quick turnover in nucleolus. We are much in favor of the second hypotheses, several evidences support our selection: (i) GFP/SVV-deltaEx3 by itself is able to localize (very inefficiently though) to nucleolus without the aid of MG132; (ii) MG132 inhibits the degradation of GFP/SVV-deltaEx3, resulting in an continued nucleolar accumulation of GFP/SVV-deltaEx3; (iii) by addition of MG132 plus CHX, the synthesis of GFP/ SVV-deltaEx3 has been ceased and the pre-existing GFP/SVV-deltaEx3 remained in an undetectable level. However, we cannot completely exclude the possibility that another protein, with a normally rapid turnover rate, artificially accumulates under proteasome inhibition, and merely carries Survivin-deltaEx3 into nucleolus. Based on the data that ectopic expression of Survivin-deltaEx3 is able to accumulate in the nucleolus in the absence of proteasome inhibitors, we propose that it may not require any 'hypothesized carrier' to transport into nucleolus, because this hypothesized unstable 'carrier' itself will be quickly degraded in the absence of GM132. Nevertheless, the real explanation still awaits further experimentations. To obtain the real explanation still awaits further experimentations. Taken together, we demonstrated that the nucleolus localization of SVV-deltaEx3 is probably not due to the transporting by proteasome inhibitors, rather is due to its intrinsic properties of SVV-deltaEx3 (for example, containing NoLS and nucleolus degradation signal), and the disappearance of nucleolar accumulation of SVV-deltaEx3 in nucleolus is owing to its rapid degradation.
To be degraded in nucleolus, protein usually needs to contain a specific degradation signal. In this study, we found that GFP/SVV-deltaEx3(92-137), which contains NoLS and degradation signal is more stable than GFP/ SVV-deltaEx3(74-137) lacking NoLS, because the nuclear fluorescent intensity of GFP/SVV-deltaEx3(92-137) is at least 1.5-2 Â higher than that of GFP/SVV-deltaEx3(74-137) by measuring their intensities ( Figure 2B , densitometry data not shown). In addition, when the degradation signal of SVV-deltaEx3 identified in this study was fused with bona fide nucleolar protein or protein peptide p14ARF or TAT-PTD and expressed in the cells, we found protein level of both p14ARF/SVV-deltaEx3(92-137) and TAT-PTD/SVV-deltaEx3(92-137) were significantly (Po0.05, t-test) decreased in nucleoli compared with p14ARF and TAT-PTD under the same conditions ( Figure 6C ), further demonstrating that nucleolus could function as an active degradation site. Coincidently, a number of recent data from other laboratories seem to be in favor of our opinion. Itahana et al demonstrated that two nucleolar proteins ARF and B23 are localized exclusively in nucleoli; ARF interacts with B23 and hence induces rapid polyubiquitination and subsequent proteosomeal degradation of B23 (Itahana et al., 2003) . In addition, proteasomes, POD proteins such as PML, Sp100 and EBNA-5, transcription factor C-myc and some regulators of apoptosis such as p53 and MDM2 have all been shown to localize to the nucleolus in response to proteasome inhibitors (Lohrum et al., 2000; Mattsson et al., 2001; Pokrovskaja et al., 2001; Arabi et al., 2003; Latonen et al., 2003) . SVV-deltaEx3 has now become a novel member of this class in which proteins are localized and degraded in nucleolus.
Materials and methods
Oligonucleotides
The sequences of the oligonucleotides used in this study are listed as follows:
Reagents and antibodies
The following antibodies were used in this study: Ab-actin (Santa Cruz Biotechnology, USA); monoclonal antibodies: mAb-GFP (MBL, Japan) and mAb-Flag (Sigma, USA). ALLN and MG132 were purchased from Calbiochem, Doxorubicin, Hoechst 33342 and cycloheximide was from Sigma. Restriction enzymes were purchased mostly from New England BioLabs. Medium compounds were obtained from Oxid (UK). Majority of biochemical reagents were ordered from Sigma.
Cell culture and transfection
HeLa and MCF-7 cell lines were maintained in DMEM containing 10% heat-inactivated fetal bovine serum (FBS), 1 Â nonessential amino acid, 100 mg/ml Penicillin, 1 Â MEM sodium pyruvate, 100 mg/ml Streptomycin (GIBCO, Grand Island, NY, USA). Cultured cells were incubated in a humidified atmosphere containing 5% CO 2 at 371C. Transfection of cells with various mammalian expression constructs by Lipofectamine 2000 (GIBCO, USA) was according to the methods provided by the manufacturer's specification.
PCR mediated-mutagenesis
To obtain the SVV-detaEx3 deletion construct SVV-detaEx3
ÀNoLS
, we have employed the PCR mediated-mutagenesis method. The primer pairs P1/P5 and P4/P3 were used to amplify two SVV-deltaEx3 fragments. The resultant two overlapping PCR fragments were mixed with equal amounts. This mixture was incubated first at 941C for 4 min, followed by first PCR (PCR1) of 941C denaturing for 1 min, 561C annealing for 1 min and 721C extension for 1 min. After 10 cycles, the PCR1 products was used as templates in a second PCR (PCR2), primed by oligonucleotides P1 and P2 and the reaction was further carried out for another 20 cycles under the same PCR conditions used in PCR1. A prominent band with expected size of 0.35 kb was visible on 1% agarose gel. Expected mutation was further verified by DNA sequencing.
Plasmids construction
The cDNA of SVV or SVV-deltaEx3 was amplified by RT-PCR from total RNA of HeLa cell line using primer pair P1/ P2 or P1/P3. The amplified fragments were cloned into the pGEM-T vector. The cDNAs of Survivin and SVV-deltaEX3 were subsequently subcloned into EcoR1/Sal1 sites of pEGFP-C1 vector (for the preparation of GFP fused proteins). DNA fragment coding for SVV-deltaEx3(1-91), , or SVV-deltaEx3(74-91) was PCRed out from SVV-deltaEx3 cDNA using primer pairs P1/P6, P7/P3, P8/P3 or P7/P6, respectively, and inserted into EcoR1/Sal1sites of pEGFP-C1 in fusion with EGFP. Plasmid pDsRed1-C1/nuceolin was a generous gift from Dr Lydie Da Costa (Laboratoire d'Hematologie, Hopital de Bicetre, Le Kremlin Bicetre, France), and pcDNA3/ARF was kindly provided by Dr John C Reed (The Burnham Institute, La Jolla, CA 92037, USA).
Apoptosis assay
HeLa cells (2 Â 10 4 cells/well) in 24-well plate were transfected with 0.3 mg mammalian expression vectors. At 20 h after transfection, cells were continued to be incubated with drug and the viability of the cells was measured by counting round apoptotic cells characterized to be with aberrant nuclei stained by Hoechst 33342. Data are expressed as percentages of control and are the means of three independent experiments. The data were all further assessed by statistical analysis, namely t-test.
Western blot analysis
The methods were described according to Song et al. (2003) . Briefly, cells were washed with 1XPBS and resuspended with 5 volumes of cold lysis buffer (50 mM Tris-HCl (pH 7.5), 250 mM NaCl, 5 mM EDTA, 50 mM NaF, 0.5% NP-40) supplemented with protease inhibitor cocktail (Roche). Cell lysate was incubated on ice for 30 min and was then centrifuged for 10 min at 41C. Equal amounts of proteins were loaded onto the gel and separated by SDS-PAGE, and the resolved proteins were transferred to nitrocellulose membrane. After blocking with 5% nonfat milk in TBST for overnight at 41C, blot was incubated with primary antibody for 1 h at room temperature. Membrane was then probed with HRP-conjugated secondary antibody for 1 h, and developed by ECL according to the manufacturer's protocol.
Fluorescence microscopy
HeLa or MCF-7 cells were grown on 24-well plate and transiently transfected with plasmids harboring the genes coding for GFP or GFP fusion proteins. After 24 h, the transfected cells were incubated with Hoechst 33342 (5 mg/ml), which is permeable to cells for 30 min to stain cell DNAs. The live cells were then examined for protein localization and chromosome staining using fluorescence microscopy. The images were further analysed by Photoshop software.
Immunoprecipitation
Cells were lysed in a Triton X-100-based lysis buffer (1% Triton X-100, 10% glycerol, 150 mM NaCl, 20 mM Tris, pH 7.5, 2 mM EDTA, protease inhibitor cocktail) for 1 h, and the nuclear and cellular debris was cleared by centrifugation. The cytosolic lysis was then mixed with GFP monoclonal antibody (mAb) bound to Protein A/G-Sepharose. After 1-h incubation at 41C, the immunoprecipitates were washed five times in lysis buffer, and proteins were recovered by boiling beads in SDS sample buffer and analysed by Western blot.
The assessment of levels of GFP fusion proteins
Protein levels were assessed by fluorescence intensity of transfected cells expressing GFP fusions by fluorescence microscope (Li et al., 1998a, b; Lenk and Sommer, 2000; Lindsten et al., 2003) . To compare the protein level more accurately, same amounts of plasmid and same conditions used for transfection were strictly employed. After transfection, the expression levels of GFP fusion proteins were compared by calculating the percentage of fluoresced cells and further confirmed by Western blot using anti-GFP antibody.
